Home › Funds › Bellevue Group AG › JBIO

Bellevue Group AG position in JBIO

JADE BIOSCIENCES INC · Health Care

Bellevue Group AG reported holding 3,057,996 shares of JBIO (JADE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$67.9M, representing 1.43% of its reported portfolio and ranking #25 among its reported holdings. Bellevue Group AG has disclosed JBIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)3.06M sh
Reported value held$67.95M
Portfolio Weight1.43%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's JBIO position evolved

Bellevue Group AG first disclosed a stake in JBIO in Q4 2025 at 3,341,103 shares (US$51.6M). The position peaked in Q2 2026 at 3,057,996 shares, worth US$67.9M. Across 3 filings, Bellevue Group AG increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,057,996 shares valued at US$67.9M — a reduction of -443,506 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q4 2025 3.34M $51.55M New
Q1 2026 3.50M $49.20M Add
Q2 2026 3.06M $67.95M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JBIO and 13F data

JBIO (JADE BIOSCIENCES INC) is a Health Care company. 106 other funds we track also report a position in JBIO — the largest reported positions include Fairmount Funds Management LLC (US$101.2M), RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JBIO

All JBIO fund holders →

FAQ

How long has Bellevue Group AG held JBIO?

Bellevue Group AG has disclosed JBIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Bellevue Group AG's current position in JBIO?

As of Q2 2026, Bellevue Group AG holds 3.06M shares of JBIO (JADE BIOSCIENCES INC), valued at $67.95M, representing 1.43% of its reported portfolio and ranking #25.

Has Bellevue Group AG been buying or selling JBIO?

In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in JBIO. The position peaked in Q2 2026 at 3.06M shares.

Which other funds hold JBIO?

Other major institutional holders of JBIO include Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, among 106 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.